HEALTH

Genentech Wins Order to Stop Hormone Sale: The South San Francisco-based biotech firm said the court order prevents rival Bio-Technology General Corp. from selling its human-growth hormone in the United States. Bio-Technology General was granted Food and Drug Administration approval May 25 to begin selling Bio-Tropin domestically, increasing competition for growth hormones made by Genentech Inc. and Eli Lilly & Co. The order, handed down by the U.S. District Court for the Southern District of New York, was granted pending the outcome of a patent-infringement suit Genentech brought against Bio-Technology General. Iselin, N.J.-based Bio-Technology General said it will appeal.